Steininger, H., Pfofe, D.A., Muller, H., Haag-Sunjic, G. and Fratianu, V. (2005) Expression of CDX2 and MUC2 in Barrett’s Mucosa. Pathology—Research and Practice, 201, 573-577.
http://dx.doi.org/10.1016/j.prp.2005.03.010

has been cited by the following article:

• TITLE: CDX2 Overexpression in Barrett’s Esophagus and Esophageal Adenocarcinoma

  AUTHORS: Leandro Almeida Streher, Vinicius Campos, Guilherme da Silva Mazzini, Marcelo Binato, Luise Meurer, Maria Isabel Edelweiss, Richard Ricachenevsky Gurski

  KEYWORDS: CDX2, Barrett’s Esophagus, Intestinal Metaplasia, Esophageal Adenocarcinoma, Immunohistochemistry

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.7, June 3, 2014

  ABSTRACT: Background: Patients with Barrett’s esophagus have an increased risk of developing esophageal adenocarcinoma. Our purpose was to determine CDX2 expression in esophageal mucosa and establish a correlation between this marker and the progression of disease. Methods: We analyzed biopsies and surgical specimens from 150 patients who were divided into five groups according to histopathological diagnosis: G1, normal mucosa (n = 29); G2, esophagitis (n = 19); G3, columnar epithelium without intestinal metaplasia (n = 26); G4, Barrett’s esophagus (n = 32), and G5, adenocarcinoma (n = 44). Immuno-histochemical determination of CDX2 expression was considered positive in the presence of nuclear staining. Results: No CDX2 expression was detected in the G1 or G3 groups; 5% of G2, 62.5% of G4 and 70.5% of G5 patients were CDX2 positive. There was a statistically significant difference between the G4 and G5 groups compared to the G1, G2 and G3 (p